Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind tremelimumab vs placebo in unresectable malignant mesothelioma
2012-003524-21Phase 2Terminated
- Sponsor
- MedImmune
- Start
- Jun 2013
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pleural mesothelioma and peritoneal mesothelioma comparing Tremelimumab arm with Placebo arm (2 arms). Primary endpoint: Overall survival. Started Jun 2013; status: terminated.
02
Drugs
tremelimumab
03
Conditions
pleural mesotheliomaperitoneal mesothelioma
Beyond the preview
Go deeper on 2012-003524-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003524-21.